5 results on '"Esser, Stefan"'
Search Results
2. Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts.
- Author
-
Esser, Stefan, Brunetta, Jason, Inciarte, Alexy, Levy, Itzchak, D'Arminio Monforte, Antonella, Lambert, John S., van Welzen, Berend, Teruya, Katsuji, Boffito, Marta, Liu, Chun‐Eng, Altuntas Aydın, Ozlem, Thorpe, David, Heinzkill, Marion, Marongiu, Andrea, Cassidy, Tali, Haubrich, Richard, D'Amato, Lisa, and Robineau, Olivier
- Subjects
- *
HIV integrase inhibitors , *COMBINATION drug therapy , *PATIENT safety , *RESEARCH funding , *SCIENTIFIC observation , *QUESTIONNAIRES , *HIV infections , *DESCRIPTIVE statistics , *PSYCHOLOGY of HIV-positive persons , *EMTRICITABINE-tenofovir , *LONGITUDINAL method , *DRUG efficacy , *HEALTH outcome assessment , *DRUG tolerance , *EVALUATION - Abstract
Background: Real‐world evidence is an essential component of evidence‐based medicine. The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatment‐naïve (TN) and treatment‐experienced (TE) people with HIV. Methods: BICSTaR is a prospective, observational cohort study. Participants (≥18 years) are being followed for 24 months. A pooled analysis is presented at 12 months, with the primary endpoint of effectiveness (HIV‐1 RNA <50 copies/mL) and secondary endpoints of safety and tolerability (as per protocol). An exploration of patient‐reported outcome measures using standardized questionnaires is included. Results: Between June 2018 and May 2021, 1552 people with HIV were enrolled across 12 countries. The analysed population comprised 1509 individuals (279 TN, 1230 TE); most were white (76%), male (84%) and had one or more comorbid conditions (68%). Median age was 47 years. After 12 months of B/F/TAF treatment, HIV‐1 RNA was <50 copies/mL in 94% (221/236) of TN participants and 97% (977/1008) of TE participants. Median CD4 cell count increased by 214 cells/μL (p < 0.001) in TN participants and 13 cells/μL (p = 0.014) in TE participants; median CD4/CD8 ratios increased by 0.30 and 0.03, respectively (both p < 0.001). Persistence was high at 12 months (TN, 97%; TE, 95%). No resistance to B/F/TAF emerged. Study drug‐related adverse events occurred in 13% of participants through 12 months, leading to B/F/TAF discontinuation in 6%. Conclusions: The findings of this study provide robust real‐world evidence to support the broad use of B/F/TAF in both TN and TE people with HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical characteristics of monkeypox virus infections among men with and without HIV : A large outbreak cohort in Germany
- Author
-
Hoffmann, Christian, primary, Jessen, Heiko, additional, Wyen, Christoph, additional, Grunwald, Stephan, additional, Noe, Sebastian, additional, Teichmann, Jörn, additional, Krauss, Anja‐Sophie, additional, Kolarikal, Henning, additional, Scholten, Stefan, additional, Schuler, Christoph, additional, Bickel, Markus, additional, Roll, Clemens, additional, Kreckel, Peter, additional, Köppe, Siegfried, additional, Straub, Matthias, additional, Klausen, Gerd, additional, Lenz, Johannes, additional, Esser, Stefan, additional, Jensen, Björn, additional, Rausch, Michael, additional, Unger, Stefan, additional, Pauli, Ramona, additional, Härter, Georg, additional, Müller, Matthias, additional, Masuhr, Anja, additional, Schäfer, Guido, additional, Seybold, Ulrich, additional, Schellberg, Sven, additional, Schneider, Jochen, additional, Monin, Malte Benedikt, additional, Wolf, Eva, additional, Spinner, Christoph D., additional, and Boesecke, Christoph, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany.
- Author
-
Hoffmann, Christian, Jessen, Heiko, Wyen, Christoph, Grunwald, Stephan, Noe, Sebastian, Teichmann, Jörn, Krauss, Anja‐Sophie, Kolarikal, Henning, Scholten, Stefan, Schuler, Christoph, Bickel, Markus, Roll, Clemens, Kreckel, Peter, Köppe, Siegfried, Straub, Matthias, Klausen, Gerd, Lenz, Johannes, Esser, Stefan, Jensen, Björn, and Rausch, Michael
- Subjects
DIAGNOSIS of HIV infections ,MEN ,MONKEYPOX ,RETROSPECTIVE studies ,ACQUISITION of data ,SEVERITY of illness index ,EPIDEMICS ,MEDICAL records ,DESCRIPTIVE statistics ,MEN who have sex with men ,COMORBIDITY ,SYMPTOMS - Abstract
Background: Since May 2022, increasing numbers of monkeypox virus (MPXV) infections have been reported from across Europe and North America. Studies, mainly from Africa, have suggested a higher risk for severe MPXV cases in people living with HIV. Methods: This was a retrospective study of all confirmed MPXV infections observed in the participating centres since 19 May 2022. We conducted a chart review to evaluate clinical characteristics, comorbidities, and coinfections, including HIV, viral hepatitis, and sexually transmitted infections (STIs). Results: By 30 June 2022, a total of 546 MPXV infections were reported from 42 German centres. All patients were men who have sex with men (MSM), of whom 256 (46.9%) were living with HIV, mostly with a preserved immune system and with viral suppression. In total, 232 (42.5%) MSM were also taking HIV pre‐exposure prophylaxis (PrEP) and 58 (10.6%) MSM had no known HIV infection or PrEP use. The median age was 39 years (range 20–67), and comorbidities were rare. However, 52.4% and 29.4% of all patients had been diagnosed with at least one STI within the last 6 months or within the last 4 weeks, respectively. The most frequent localizations of MPXV infection were genital (49.9%) and anal (47.9%), whereas fever (53.2%) and lymphadenopathy (42.6%) were the most frequent general symptoms. The hospitalization rate was low (4.0%), and no fatal course was observed. The clinical picture showed no apparent differences between MSM with or without HIV. Conclusions: In this preliminary cohort analysis from a current large outbreak among MSM in Germany, the clinical picture of MPXV infection did not differ between MSM with and without HIV infection. Severe courses were rare and hospitalization rates were low. However, most patients were relatively healthy, and only a few people living with HIV were viremic or severely immunosuppressed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Summary of German‐Austrian HIV PrEP guideline.
- Author
-
Spinner, CD, Lang, GF, Boesecke, C, Jessen, H, Schewe, K, Stellbrink, Hans‐Jürgen, Esser, Stefan, Haberl, Annette, Römer, Katja, Plettenberg, Andreas, Rockstroh, Jürgen, Scholten, Stefan, Weber, Christoph, Haas, Bernhard, Lehmann, Clara, de Leuw, Philipp, Brockmeyer, Norbert, Schmiedel, Stefan, Kaiser, Rolf, and Marcus, Ulrich
- Subjects
HIV prevention ,INFECTIOUS disease transmission ,COUNSELING ,MEDICAL protocols ,PREVENTIVE medicine - Abstract
Objectives: HIV Pre‐Exposure prophylaxis (PrEP) is a strategy to reduce HIV transmission in people at risk. Aim of this first German‐Austrian PrEP guideline is to provide professional guidance on: when and in whom to use PrEP, recommended laboratory tests before and while on PrEP, selection of drugs, prevention of adverse events as a consequence of missing accompanying medical care, and general handling of PrEP in adults and adolescents. Methods: Commented summary of of the S2k PrEP consensus guidelines released by the German and Austrian HIV medical societies to highlight the key recommendations of the guidelines. Content: Detailed information about effectiveness of PrEP, when and in whom to use PrEP, as well as about additional monitoring of HIV PrEP are included in the HIV PrEP guidelines. Therewith detailed guidance for people being involved in PrEP counseling and associated care is provided. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.